PURPOSE: To explore decline in visual acuity in @entity1 with neovascular age-related @entity1020 (n- @entity13785 ) awaiting intravitreal bevacizumab or ranibizumab treatment following initial diagnosis and after disease reactivation. METHODS: Retrospective analysis of 74 treatment-na  ve @entity1 (84 eyes) in two centers in C  rdoba, Argentina. The time between treatment indication and intravitreal injection, and the changes in BCVA produced during this delay were studied in both periods. A linear regression model to search the impact of time on progression @entity227 was conducted. RESULTS: In both periods, a significant reduction in vision occurred awaiting intravitreal injection. The longer the delay, the greater the @entity1018 (R2   =   0.55 p   <   0.01) and the less improvement following treatment (Pearson coefficient -0.26). The result of the model shows that the change in vision as a function of initial delay were best described by a polynomic model with a mean loss of 5 letters in the first 3  weeks, a slowdown in the rate of change of VA, and a dependence of visual acuity at the moment of diagnosis . The loss of visual acuity after reactivation shows the same behavior as at the onset of the disease but independent of visual acuity prior to reactivation. CONCLUSION: @entity227 awaiting injection intravitreal anti- @entity7 is clinically significant and with an asymptotic pattern, with early rapid @entity1018 in both the onset of the disease and the reactivation. Initiation of anti- @entity7 treatment must be undertaken urgently, as should retreatment of disease activation to reduce @entity227 .

Rate of XXXX in neovascular age-related @entity1020 explored.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1018 :: ('MESH:D054062', 'Disease') :: ['loss of vision', 'vision loss'] @entity227 :: ('MESH:D014786', 'Disease') :: ['Visual loss', 'visual loss', 'visual impairment'] @entity7 :: ('7422', 'Gene') :: ['VEGF'] @entity13785 :: ('MESH:D006009', 'Disease') :: ['AMD'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['macular degeneration']
@entity1018 :: (MESH:D054062,Disease) :: ['vision loss']
